Altimmune’s stock pops as analysts see obesity-drug partnership potential

Altimmune shares have jumped this week as analysts see potential for the company to find a partner for its experimental weight-loss drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.